お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
990199

症候群マルチプレックス診断市場:国、症候群(呼吸器、敗血症、Giなど)別の予測(2021年~2025年)、Covid-19の影響、戦略と動向による市場分析、エグゼクティブガイド、カスタマイズ

Syndromic Multiplex Diagnostic Markets with Covid-19 Impacts. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, Gi Etc.) by Country. with Market Analysis, Executive Guides and Customization. 2021 to 2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 453 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.75円
症候群マルチプレックス診断市場:国、症候群(呼吸器、敗血症、Giなど)別の予測(2021年~2025年)、Covid-19の影響、戦略と動向による市場分析、エグゼクティブガイド、カスタマイズ
出版日: 2021年02月19日
発行: Howe Sound Research
ページ情報: 英文 453 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、世界の症候群マルチプレックス診断市場について調査しており、感染症の概要、市場の成長および抑制要因、最近の開発や業界の動向、症候群・場所・国別の市場分析、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

市場ガイド

  • 状況分析とCOVIDの影響の概要
  • エグゼクティブおよびマーケティングスタッフのためのガイド
  • 投資アナリストおよび経営コンサルタントのためのガイド
  • 大手企業の市場シェア:表とグラフ

第1章 イントロダクションと市場の定義

  • 症候群マルチプレックス検査とは何か
  • 症候群検査:診断における静かな革命
  • 市場の定義
  • 調査手法
  • 米国の医療市場と臨床検査:展望
    • 臨床試験のための米国のメディケア支出

第2章 感染症:病原体へのガイド

  • コロナウイルス
    • 重症急性呼吸器症候群(SARS)
    • 中東呼吸器症候群(MERS)
    • COVID-19(新型コロナウイルス感染症)SARS CoV2ウイルス
  • HIV-ヒト免疫不全ウイルス(AIDS)
    • ウイルス学
    • 診断
    • 検査
  • HBV-B型肝炎
    • ウイルス学
    • メカニズム
    • 診断
    • 市場機会分析
  • HCV-C型肝炎
    • 分類法
    • 分子生物学
    • レプリケーション
    • 遺伝子型
    • 市場機会分析
  • HPV-ヒトパピローマウイルス
    • ウイルス学
    • 診断
    • 市場機会分析
  • インフルエンザ
    • ウイルス学
    • テスト
    • 市場機会分析
  • CTGC-クラミジア/淋病
    • 淋病
    • クラミジア
    • テスト
    • 市場機会分析
  • 結核
    • マイコバクテリア
    • 診断
    • 疫学
    • 分子診断テスト
    • 市場機会分析
  • MRSA-メチシリン耐性黄色ブドウ球菌
    • 診断
    • FDA承認の分子検査
    • 市場機会分析
  • VRE-バンコマイシン耐性腸球菌
    • FDAのVREのMDx検査承認
    • 市場機会分析

第3章 業界の概要

  • 業界の参入企業
    • IVDサプライヤー
    • 独立した専門ラボ
    • 独立したラボの全国/地域
    • 独立したラボ分析
    • 公立国立/地域研究所
    • 病院ラボ
    • 医師ラボ
    • 監査機関
  • 臨床検査市場セグメント
    • 従来の市場セグメンテーション
    • ラボの焦点とセグメンテーション
    • 症候群検査市場のセグメント化
  • 業界構造
    • 病院テストシェア
    • 規模の経済
    • 医院研究所
    • 医師とPOCT

第4章 市場動向

  • 成長を促進する要因
    • 診断のスピード
    • 症候群検査が費用に及ぼす影響
    • ポイントオブケアの利点
    • 症候群の検査、精度および診断リスク
    • 1回のみの来院
    • 結果の改善
    • COVID-19パンデミックの影響
  • 成長を制限する要因
    • 低価格
    • 管理/償還
    • 感染症減少の一方で...
    • ウェルネスによる害
    • 生活水準を向上させる経済成長
    • パンデミック不況の影響
  • 計装と自動化
    • 市場シェアの鍵となる機器
    • シュリンクマシン
    • 症候群検査機器の見通し
  • 診断技術の開発
    • 症候群と標的検査の比較
    • マルチプレックスパラダイムシフト
    • 敗血症検査市場-症候群のベルウェザー
    • 1回の来院と抗菌薬耐性
    • POCTの採用を促進する症候群
    • PCRの今後

第5章 症候群検査の最近の開発

  • 最近の開発
  • 開発の重要性
  • セクションの使用方法
  • Luminex Lands BARDA:SARS-CoV-2、インフルエンザ、RSVの検査法を開発するための助成金
  • Molzym、Fraunhofer:迅速敗血症診断の開発
  • MiRxes:マルチプレックスSARS-CoV-2、インフルエンザ検査の承認
  • Scanogen:90分間マルチプレックス検査用のポータブルバッテリー駆動機器
  • Qiagen:成長手段と見なされるNeuMoDx
  • Roche:SpeeDx提携による抗生物質耐性検査へのアクセス拡大
  • BioMrieux:BioFireSARS-CoV-2呼吸器パネルがFDAEAUを受賞
  • ChromaCode:1,000万米ドルの追加資金調達
  • COVID-19患者の症候群検査の必要性
  • コロナウイルス標的を有するQiagen呼吸器パネルのCEマーク取得
  • bioMrieux:強化されたBIOFIREBCID2パネルのFDAへの申請
  • Nanomix:診断用CEマークの取得、など
  • 主要症候群検査企業のプロファイル
    • Abacus Diagnostica
    • Abbott Diagnostics
    • Accelerate Diagnostics
    • Ador Diagnostics
    • Akonni Biosystems
    • Alveo Technologies
    • Applied BioCode
    • Aus Diagnostics
    • Beckman Coulter Diagnostics
    • Becton, Dickinson and Company
    • Binx Health
    • Biocartis
    • bioMrieux Diagnostics
    • Bio-Rad Laboratories, Inc.
    • Bosch Healthcare Solutions GmbH
    • Cepheid (now Danaher)
    • Credo Diagnostics Biomedical
    • Cue Health
    • Curetis NV / Curetis GmbH
    • Diagenode Diagnostics
    • Diasorin SpA
    • Enzo Life Sciences, Inc.
    • Eurofins Scientific
    • Fluxergy
    • Fusion Genomics
    • Genetic Signatures
    • GenMark Dx
    • Hibergene Diagnostics
    • Hologic
    • Immunexpress
    • Inflammatix
    • Invetech
    • Janssen Diagnostics
    • Karius
    • Lexagene
    • LightDeck Diagnostics
    • Luminex Corp
    • Maxim Biomedical
    • Meridian Bioscience
    • Mesa Biotech
    • Millipore Sigma
    • Mobidiag
    • Nanomix
    • Operon
    • Oxford Nanopore Technologies
    • Panagene
    • Perkin Elmer
    • Primerdesign
    • Prominex
    • Qiagen Gmbh
    • Quantumdx
    • Quidel
    • Roche Molecular Diagnostics
    • Saw Diagnostics
    • Seegene
    • Siemens Healthineers
    • Sona Nanotech
    • SpeeDx
    • T2 Biosystems
    • Thermo Fisher Scientific Inc
    • Veramarx
    • XCR Diagnostics

第6章 世界市場

  • 国別の世界市場概要
  • 症候群別の世界市場概要
  • 場所別の世界市場概要

第7章 市場分析:症候群別

  • 呼吸器
  • 胃腸
  • 血液
  • 髄膜炎/脳炎
  • 性感染症
  • その他

第8章 市場分析:場所別

  • 病院ラボ
  • 外来研究室
  • POC
  • その他

付録

  • 米国のメディケアシステム:2021年の臨床検査費スケジュール
図表

Table of Tables

  • Table 1 Market Share of Leading Companies
  • Table 2 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 3 Characteristics of Coronavirus Pandemic Infections
  • Table 4 COVID-19 Symptoms
  • Table 5 Classification of HIV Species
  • Table 6 HBV Tests - CMS Codes & Prices
  • Table 7 HCV Tests - CMS Codes & Prices
  • Table 8 HPV Clearance Rates
  • Table 9 HPV Tests - CMS Codes & Prices
  • Table 10 HPV Tests, Technology, Types
  • Table 11 Types of Influenza Tests
  • Table 12 Influenza Tests - CMS Codes & Prices
  • Table 13 FDA Cleared Molecular Assays for Influenza
  • Table 14 FDA Cleared NAAT CTGC Tests
  • Table 15 CTGC NAAT Target Sequences and Possible False Reactions
  • Table 16 Influenza Tests - CMS Codes & Prices
  • Table 17 FDA Approved MDx Tests for Tuberculosis
  • Table 18 Tuberculosis Tests - CMS Codes & Prices
  • Table 19 FDA Approved Tests for MRSA
  • Table 20 MRSA Tests - CMS Codes & Prices
  • Table 21 FDA Approved Tests for VRE
  • Table 22 VRE Tests - CMS Codes & Prices
  • Table 23 FDA Approved Tests for VRE
  • Table 24 VRE Tests - CMS Codes & Prices
  • Table 25 Market Players by Type
  • Table 26 Clinical Laboratory Departments and Segments
  • Table 27 Laboratory Management Focus - Different Approaches
  • Table 28 Key Segmentation Variables Going Forward
  • Table 29 Possible Market Segments of Syndromic Multiplex Market
  • Table 30 Five Factors Driving Growth
  • Table 31 How SMT Improves Outcomes
  • Table 32 Four Factors Limiting Growth
  • Table 33 - Global Market by Region
  • Table 34 Global Market by Syndrome
  • Table 35 Global Market by Place
  • Table 36 Respiratory by Country
  • Table 37 Gastrointestinal by Country
  • Table 38 Blood by Country
  • Table 39 Meningitis/Encephalitis by Country
  • Table 40 Sexually Transmitted Disease by Country
  • Table 41 Other by Country
  • Table 42 Hospital Lab by Country
  • Table 43 Outpatient Lab by Country
  • Table 44 POC by Country
  • Table 45 Other by Country
  • Table 46 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Market Share of Leading Companies Chart
  • Figure 2 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • FIGURE 3 STRUCTURE OF CORONAVIRUSES
  • Figure 4 HIV Virion
  • Figure 5 Diagram of the HIV Replication Cycle
  • Figure 6 The Structure of the HBV Virus
  • Figure 7 Hepatitis B Replication
  • Figure 8 Structure of the HCV Virus
  • Figure 9 HCV Replication Cycle
  • Figure 10 Structure of the Influenza Virion
  • Figure 11 Influenza Replication
  • Figure 12 Scanning Electronmicrograph of Tuberculosis
  • Figure 13 Chart Death Rates and Infectious Disease Decline
  • Figure 14 Comparing Syndromic and Targeted Testing
  • Figure 15 The Multiplex Paradigm Shift
  • Figure 16 Global Market Share Chart
  • Figure 17 Global Market by Syndrome - Base vs. Final
  • Figure 18 Global Market by Syndrome Base Year
  • Figure 19 Global Market by Syndrome End Year
  • Figure 20 Syndrome Share by Year
  • Figure 21 Syndrome Segments Growth
  • Figure 22 Global Market by Place - Base vs. Final
  • Figure 23 Global Market by Place Base Year
  • Figure 24 Global Market by Place End Year
  • Figure 25 Place Share by Year
  • Figure 26 Place Segments Growth
  • Figure 27 Respiratory Growth
  • Figure 28 Gastrointestinal Diagnostics Growth
  • Figure 29 Blood Growth
  • Figure 30 Meningitis/Encephalitis Growth
  • Figure 31 Sexually Transmitted Disease Growth
  • Figure 32 Other Growth
  • Figure 33 Hospital Lab Growth
  • Figure 34 Outpatient Lab Growth
  • Figure 35 POC Growth
  • Figure 36 Other Growth
目次

OVERVIEW:

How will COVID-19 affect Syndromic and Infectious Disease Diagnostics? The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.

Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?

Syndromic testing is proving itself in the market. Players are reporting double digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks. The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time. The report forecasts the market size out to 2024. In a special section the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel based ordering of infectious disease tests.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Market Guides

  • iA. Situation Analysis & COVID Impact Overview
  • iB. Guide for Executives and Marketing Staff
  • iC. Guide for Investment Analysts and Management Consultants
  • iD. Market Shares of Leading Companies - Table and Chart

1. Introduction and Market Definition

  • 1.1 What are Syndromic Multiplex Tests?
  • 1.2 Syndromic Testing - the quiet revolution in diagnostics
    • 1.2.1 Syndromic Testing - more than Panels.
  • 1.3 Market Definition
    • 1.3.1 Multiplex Market Size
    • 1.3.2 Currency
    • 1.3.3 Years
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
    • 1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases - Guide to the Pathogens

  • 2.0 The Coronavirus
    • 2.0.1 Severe acute respiratory syndrome (SARS)
    • 2.0.2 Middle East respiratory syndrome (MERS)
    • 2.0.3 COVID-19. The SARS CoV 2 Virus
      • 2.0.3.1 Signs and symptoms
      • 2.0.3.2 Transmission
      • 2.0.3.3 Diagnosis
      • 2.0.3.4 Prevention
      • 2.0.3.5 Management
      • 2.0.3.6 Prognosis
      • 2.0.3.7 New Strains and Subsequent Mutations
  • 2.1 HIV - Human Immunodeficiency Virus (AIDS)
    • 2.1.1 Virology
      • 2.1.1.1 Classification
      • 2.1.1.2 Structure and genome
      • 2.1.1.3 Tropism
      • 2.1.1.4 Replication cycle
      • 2.1.1.5 Genetic variability
    • 2.1.2 Diagnosis
    • 2.1.3 Testing
      • 2.1.3.1 Antibody tests
      • 2.1.3.2 Point of Care Tests (POCT)
      • 2.1.3.4 Antigen Tests
      • 2.1.3.5 Nucleic acid-based tests (NAT)
      • 2.1.3.6 Other tests used in HIV treatment
  • 2.2 HBV - Hepatitis B
    • 2.2.1 Virology
      • 2.2.1.1 Genome
      • 2.2.1.2 Pathogenesis
      • 2.2.1.3 Hepatitis B virus replication
      • 2.2.1.4 Serotypes and genotypes
    • 2.2.2 Mechanisms
    • 2.2.3 Diagnosis
    • 2.2.4 Market Opportunity Analysis
  • 2.3 HCV - Hepatitis C
    • 2.3.1 Taxonomy
      • 2.3.2.1 Structure
      • 2.3.2.2 Genome
    • 2.3.3 Molecular biology
    • 2.3.4 Replication
    • 2.3.5 Genotypes
      • 2.3.5.1 Clinical importance
    • 2.3.6 Market Opportunity Analysis
  • 2.4 HPV - Human papillomavirus
    • 2.4.1 Virology
      • 2.4.1.1 E6/E7 proteins
      • 2.4.1.2 Role in cancer
      • 2.4.1.3 E2 research
      • 2.4.1.4 Latency period
      • 2.4.1.5 Clearance
    • 2.4.2 Diagnosis
      • 2.4.2.1 Cervical testing
      • 2.4.2.2 Oral testing
      • 2.4.2.3 Testing men
      • 2.4.2.4 Other testing
    • 2.4.3 Market Opportunity Analysis
  • 2.5 Influenza
    • 2.5.1 Virology
      • 2.5.1.1 Types of virus
      • 2.5.1.2 Influenzavirus A
      • 2.5.1.3 Influenzavirus B
      • 2.5.1.4 Influenzavirus C
      • 2.5.1.5 Structure, properties, and subtype nomenclature
      • 2.5.1.6 Replication
    • 2.5.2 Testing
      • 2.5.2.1 Advantages/Disadvantages of Molecular Assays
    • 2.5.3 Market Opportunity Analysis
  • 2.6 CTGC - Chlamydia/Gonorhea
    • 2.6.1 Gonorrhea
      • 2.6.1.1 Diagnosis
      • 2.6.1.2 Screening
    • 2.6.2 Chlamydia
      • 2.6.2.1 Diagnosis
      • 2.6.2.2 Screening
    • 2.6.3 Testing
      • 2.6.3.1 Nucleic acid amplification tests (NAATs).
      • 2.6.3.2 Performance of NAAT Tests
    • 2.6.4 Market Opportunity Analysis
  • 2.7 Tuberculosis
    • 2.7.1 Mycobacteria
    • 2.7.2 Diagnosis
      • 2.7.2.1 Active tuberculosis
      • 2.7.2.2 Latent tuberculosis
    • 2.7.3 Epidemiology
    • 2.7.4 Molecular Diagnostic Tests
    • 2.7.5 Market Opportunity Analysis
  • 2.8 MRSA - Methicillin-resistant Staphylococcus aureus
    • 2.8.1 Diagnosis
    • 2.8.2 FDA Approved Molecular Tests
    • 2.8.3 Market Opportunity Analysis
  • 2.9 VRE - Vancomycin-resistant Enterococcus
    • 2.9.1 FDA Approved MDx Tests for VRE
    • 2.9.2 Market Opportunity Analysis
  • 2.10 VRE - Vancomycin-resistant Enterococcus
    • 2.9.1 FDA Approved MDx Tests for VRE
    • 2.9.2 Market Opportunity Analysis

3. Industry Overview

  • 3.1 Industry Participants
    • 3.1.1 IVD Supplier
    • 3.1.2 Independent lab specialized/esoteric
    • 3.1.3 Independent lab national/regional
    • 3.1.4 Independent lab analytical
    • 3.1.5 Public National/regional lab
    • 3.1.6 Hospital lab
    • 3.1.7 Physician lab
    • 3.1.8 Audit body
  • 3.2 The Clinical Laboratory Market Segments
    • 3.2.1 Traditional Market Segmentation
    • 3.2.2 Laboratory Focus and Segmentation
    • 3.2.3 Segmenting the Syndromic Testing Market
  • 3.3 Industry Structure
    • 3.3.1 Hospital Testing Share
    • 3.3.2 Economies of Scale
      • 3.3.2.1 Hospital vs. Central Lab
    • 3.3.3 Physician Office Lab's
    • 3.3.4 Physician's and POCT

4. Market Trends

  • 4.1 Factors Driving Growth
    • 4.1.1 Speed of Diagnosis
    • 4.1.2 Effect of Syndromic Testing on Costs.
    • 4.1.3 Point of Care Advantage.
    • 4.1.4 Syndrome Testing, Accuracy and Diagnostic Risk
    • 4.1.5 Single Visits
    • 4.1.6 Improvement in Outcomes.
    • 4.1.7 Impact of the COVID-19 Pandemic.
  • 4.2 Factors Limiting Growth
    • 4.2.1 Lower Prices
    • 4.2.2 Administration/reimbursement
    • 4.2.3 Infectious Disease is Declining But....
    • 4.2.4 Wellness Hurts
    • 4.2.5 Economic Growth improves Living Standards
    • 4.2.6 Impact of the Pandemic Recession
  • 4.3 Instrumentation and Automation
    • 4.3.1 Instruments Key to Market Share
    • 4.3.2 The Shrinking Machine.
    • 4.3.3 Syndrome Testing Moving to Big Instruments?
  • 4.4 Diagnostic Technology Development
    • 4.4.1 Comparing Syndrome and Targeted Testing
    • 4.4.2 The Multiplex Paradigm Shift
    • 4.4.2 The Sepsis Testing Market - Bellwether for Syndromics
    • 4.4.3 The Single Visit and AntiMicrobial Resistance
    • 4.4.4 Syndromics drives POCT adoption
    • 4.4.5 A Big Future for PCR?

5. Syndromic Testing Recent Developments

  • Recent Developments - Importance and How to Use This Section
  • Importance of These Developments
  • How to Use This Section
  • Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
  • Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic
  • MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test
  • New Approach Involves Silicon-Based Test for Infectious Disease Screening
  • Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test
  • Qiagen sees NeuMoDx as Growth Vehicle
  • Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround
  • Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests
  • BioMérieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
  • Infectious Disease Testing Firm Curative Acquires KorvaLabs
  • ChromaCode Raises Additional $10M
  • COVID-19 Patients Need Syndromic Testing
  • GenMark Diagnostics - New Respiratory Panel due in June
  • Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
  • Exact Diagnostics launches respiratory panel control
  • bioMérieux submits enhanced BIOFIRE® BCID2 Panel to FDA
  • Nanomix Receives CE Mark for Diagnostic
  • Applied BioCode Applies to FDA for Syndromic Respiratory Panel
  • Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
  • QIAGEN's New GI Panel Performance Assessed
  • McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
  • Applied BioCode Obtains FDA Clearance
  • Meridian Bioscience to Acquire GenePOC Inc
  • Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
  • Qiagen gets FDA clearance for syndromic testing system
  • Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMérieux
  • Akonni Biosystems Submits Multiplex Diagnostics System to FDA
  • Ador Diagnostic to receive $30M in Funding for 100-Plex PoC
  • SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
  • QuantuMDx and Molbio announce MoU
  • Immunexpress Wins $745K Contract for Rapid Sepsis Assay
  • Mobidiag Inks European, Middle Eastern Distribution Deals
  • BIOFIRE® FILMARRAY® System chosen for Phase 3 clinical trial
  • 5.1 Profiles of Key Syndromic Testing Companies
    • Abacus Diagnostica
    • Abbott Diagnostics
    • Accelerate Diagnostics
    • Ador Diagnostics
    • Akonni Biosystems
    • Alveo Technologies
    • Applied BioCode
    • Aus Diagnostics
    • Beckman Coulter Diagnostics
    • Becton, Dickinson and Company
    • Binx Health
    • Biocartis
    • bioMérieux Diagnostics
    • Bio-Rad Laboratories, Inc.
    • Bosch Healthcare Solutions GmbH
    • Cepheid (now Danaher)
    • Credo Diagnostics Biomedical
    • Cue Health
    • Curetis N.V. / Curetis GmbH
    • Diagenode Diagnostics
    • Diasorin S.p.A.
    • Enzo Life Sciences, Inc.
    • Eurofins Scientific
    • Fluxergy
    • Fusion Genomics
    • Genetic Signatures
    • GenMark Dx
    • Hibergene Diagnostics
    • Hologic
    • Immunexpress
    • Inflammatix
    • Invetech
    • Janssen Diagnostics
    • Karius
    • Lexagene
    • LightDeck Diagnostics
    • Luminex Corp
    • Maxim Biomedical
    • Meridian Bioscience
    • Mesa Biotech
    • Millipore Sigma
    • Mobidiag
    • Nanomix
    • Operon
    • Oxford Nanopore Technologies
    • Panagene
    • Perkin Elmer
    • Primerdesign
    • Prominex
    • Qiagen Gmbh
    • Quantumdx
    • Quidel
    • Roche Molecular Diagnostics
    • Saw Diagnostics
    • Seegene
    • Siemens Healthineers
    • Sona Nanotech
    • SpeeDx
    • T2 Biosystems
    • Thermo Fisher Scientific Inc
    • Veramarx
    • XCR Diagnostics

6. The Global Market for Syndromic Multiplex Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Syndrome - Overview
    • 6.2.1 Table - Global Market by Syndrome
    • 6.2.2 Chart - Global Market by Syndrome - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Syndrome - Base Year
    • 6.2.4 Chart - Global Market by Syndrome - End Year
    • 6.2.5 Chart - Global Market by Syndrome - Share by Year
    • 6.2.6 Chart - Global Market by Syndrome - Segments Growth
  • 6.3 Global Market by Place - Overview
    • 6.3.1 Table - Global Market by Place
    • 6.3.2 Chart - Global Market by Place - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market by Place - Base Year
    • 6.3.4 Chart - Global Market by Place - End Year
    • 6.3.5 Chart - Global Market by Place - Share by Year
    • 6.3.6 Chart - Global Market by Place - Segments Growth

7. Global Syndromic Multiplex Markets - By Syndrome

  • 7.1 Respiratory
    • 7.1.1 Table Respiratory - by Country
    • 7.1.2 Chart - Respiratory Growth
  • 7.2 Gastrointestinal
    • 7.2.1 Table Gastrointestinal - by Country
    • 7.2.2 Chart - Gastrointestinal Growth
  • 7.3 Blood
    • 7.3.1 Table Blood - by Country
    • 7.3.2 Chart - Blood Growth
  • 7.4 Meningitis/Encephalitis
    • 7.4.1 Table Meningitis/Encephalitis - by Country
    • 7.4.2 Chart - Meningitis/Encephalitis Growth
  • 7.5 Sexually Transmitted Disease
    • 7.5.1 Table Sexually Transmitted Disease - by Country
    • 7.5.2 Chart - Sexually Transmitted Disease Growth
  • 7.6 Other
    • 7.6.1 Table Other - by Country
    • 7.6.2 Chart - Other Growth

8. Global MDx Infectious Disease Markets - by Place

  • 8.1 Hospital Lab
    • 8.1.1 Table Hospital Lab - by Country
    • 8.1.2 Chart - Hospital Lab Growth
  • 8.2 Outpatient Lab
    • 8.2.1 Table Outpatient Lab - by Country
    • 8.2.2 Chart - Outpatient Lab Growth
  • 8.3 POC
    • 8.3.1 Table POC - by Country
    • 8.3.2 Chart - POC Growth
  • 8.4 Other Technology
    • 8.4.1 Table Other - by Country
    • 8.4.2 Chart - Other Growth

Appendices

  • I. United States Medicare System: 2021 Clinical Laboratory Fees Schedule
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.